TCL Archive Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer July 31, 2009
TCL Archive Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent January 27, 2012
TCL Archive In Brief: Deadline June 1 For Cancer Research Institute Grants; Chabner To Present Karnofsky Lecture May 3, 1985